scholarly journals Characteristics of Pain Assessed with Visual Analog Scale and Questionnaire in Burning Mouth Syndrome Patients: A Pilot Study

2013 ◽  
Vol 27 (3) ◽  
pp. 235-242 ◽  
Author(s):  
Adeline Braud ◽  
Babacar Toure ◽  
Scarlette Agbo-Godeau ◽  
Vianney Descroix ◽  
Yves Boucher
2006 ◽  
Vol 13 (7) ◽  
pp. e6-e7 ◽  
Author(s):  
S. M. Heckmann ◽  
J. G. Heckmann ◽  
A. Ungethum ◽  
P. Hujoel ◽  
T. Hummel

2011 ◽  
Vol 51 (3) ◽  
pp. 444-446 ◽  
Author(s):  
Alan R. Hirsch ◽  
Alhumayyd Ziad ◽  
Ah Young Kim ◽  
Navdeep Singh Lail ◽  
Sameer Sharma

2010 ◽  
Vol 28 (6) ◽  
pp. 835-839 ◽  
Author(s):  
Ilka Tiemy Kato ◽  
Vivian Diane Pellegrini ◽  
Renato Araujo Prates ◽  
Martha Simões Ribeiro ◽  
Niklaus Ursus Wetter ◽  
...  

2018 ◽  
Vol 29 (6) ◽  
pp. 623-629 ◽  
Author(s):  
Daniela Adamo ◽  
Michele Davide Mignogna ◽  
Giuseppe Pecoraro ◽  
Massimo Aria ◽  
Giulio Fortuna

Pain Medicine ◽  
2019 ◽  
Author(s):  
Daniela Adamo ◽  
Giuseppe Pecoraro ◽  
Massimo Aria ◽  
Gianfranco Favia ◽  
Michele Davide Mignogna

Abstract Objective To evaluate the efficacy of a new multimodal antidepressant, vortioxetine (VO), in the management of burning mouth syndrome (BMS). Design Longitudinal single-assessment open-label pilot study. Setting University hospital. Subjects. Thirty BMS patients were enrolled. Methods BMS patients were treated with topical clonazepam and a flexible dose of VO (10 mg, 15 mg, or 20 mg). The visual analog scale (VAS), the Total Pain Rating Index (T-PRI), the Hamilton Rating Scales for Depression (HAM-D) and Anxiety (HAM-A), and the Pittsburgh Sleep Quality Index (PSQI) were performed at baseline (time 0) and after two (time 1), four (time 2), six (time 3), and 12 months (time 4) of treatment. Descriptive statistics and the Wilcoxon nonparametric test for two paired samples were used. Results The BMS patients showed a statistically significant improvement in VAS and T-PRI scores from baseline (median [interquartile range {IQR}] = 10.0 [10–10] and 22.0 [20–24], respectively) to time 4 (median [IQR] = 0.0 [0–0] and 8.0 [7–9], P < 0.001, respectively). Similarly, the HAM-A and HAM-D and PSQI scores showed an improvement from time 0 (median [IQR] = 20 [15.8–22], 19 [16–20.3], and 4.0 [4–7.3], respectively) to time 4 (median [IQR] = 6.0 [6–7], 6.0 [6–7], and 3.0 [3–4], respectively, P < 0.001). Conclusions VO is efficacious and well tolerated in the treatment of BMS in firstline therapy on account of its better receptor pharmacological profile and in second-line treatment for patients who have only partially responded or have reported adverse effects to previous treatments.


Author(s):  
EMANUELLA CÉSAR ROCHA ◽  
ÍTALA LAÍS RODRIGUES ◽  
VANESSA FONTENELE MARQUES ◽  
FÁBIO WILDSON GURGEL COSTA ◽  
KARUZA MARIA ALVES PEREIRA ◽  
...  

2016 ◽  
Vol 31 (4) ◽  
pp. 811-816 ◽  
Author(s):  
Paolo G. Arduino ◽  
Adriana Cafaro ◽  
Marco Garrone ◽  
Alessio Gambino ◽  
Marco Cabras ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document